Damian Wójtowicz

Assistant Profesor

University of Warsaw
Country flagPoland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Damian Wójtowicz is an Assistant Professor at the University of Warsaw, Poland. His research areas encompass mutational signatures, DNA damage and repair mechanisms in cancer, and the impact of environmental exposures on biological processes. Recent publications include studies on repair deconvolution, drug sensitivity subnetworks, and network models related to mutational processes.

Articles (9)

Mutational signatures are characteristic patterns of mutation frequencies assumed to be generated by specific mutagenic processes. A growing catalog of mutational signatures exists, but tools to systematically infer relationships between them remain limited. A mutational signature can be viewed as the combined outcome of two processes: DNA damage and DNA repair. Since cancer therapies often target DNA repair, inferring DNA repair pathways is important for treatment design, even when the mutagenic process is unknown. Here, we model the DNA repair step as a transformation, called RePrint, from damaged nucleotides to repair-related mutation patterns conditioned on the damage. We demonstrate that RePrint similarity is indicative of shared DNA repair mechanisms, enabling guilt-by-association prediction of DNA repair pathways. Using experimentally annotated signatures from environmental exposures and CRISPR gene knockouts as gold standards, we demonstrate that RePrint-based clustering consistently outperforms signature-based clustering across multiple evaluation metrics. We validate several guilt-by-association predictions with literature evidence, demonstrating RePrint’s ability to identify shared repair mechanisms even among signatures with divergent mutational profiles. RePrint provides the first approach to systematically transfer DNA repair information between signatures, opening doors to understanding signatures of unknown origin and informing therapeutic strategies. An open-source implementation is available at https://github.com/wojtowicz-lab/RePrintPy

Year:

2026

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related death despite the availability of therapies targeting the tumor microenvironment (TME) and/or the tumor. Immunotherapy and novel targeted therapy have improved the management of NSCLC, but the heterogeneity of the disease still hampers treatment efficacy as well as further therapeutic advances. Here, we used spatial single-cell data complemented with bulk RNAseq and whole exome sequencing to investigate the TME of 192 resected, mostly early-stage NSCLC tumors and to characterize associations of genetic, clinical and lifestyle factors with cellular and histological properties of the TME. We found, that the TME of squamous cell carcinoma (LUSC) harbored stronger signs of inflammation and immune exhaustion than adenocarcinoma (LUAD), but interestingly that elevated PD-L1 expression was associated with inflammation and markers of lymphocyte activation/exhaustion only in LUAD. Smoking correlated with T cell infiltration and TP53 mutation in LUAD, and TP53 mutation was associated with proliferation of tumor cells. In both histologies, naïve and BCL2 + T cells decreased with higher clinical stages. EGFR -driven tumors showed fewer proliferating, activated and exhausted T cells, but more CD4 T cells and HLA-DR+ tumor cells, than tumors with wild type EGFR. Multi-modal integration of our four data types showed that most variation in our cohort was along the axes of histology, smoking, TP53 mutation, and inflammation. Our integration identified histology-specific prognostic signatures, with a LUSC-enriched profile of proliferation, inflammation, and smoking associated with poor prognosis in LUAD. In summary, we provide a rich, multimodal, single-cell characterization of a large NSCLC cohort as a resource and suggest that future investigations of biomarkers for ICI in NSCLC will benefit from stratification by histology.

Year:

2025

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Bernd Bodenmiller

University of Zurich

SWITZERLAND
View details

Teresa Przytycka

senior investigator

National Institutes of Health

UNITED STATES
View details

Roded Sharan

Academic, Full Professor, Full Professor

Tel Aviv University

ISRAEL
View details

Ewa Szczurek

Director

University of Warsaw

POLAND
View details